Copyright: ©Author(s) 2026.
World J Gastroenterol. Nov 28, 2026; 32(44): 122876
Published online Nov 28, 2026. doi: 10.3748/wjg.122876
Published online Nov 28, 2026. doi: 10.3748/wjg.122876
Figure 5 Scatter plot of incremental cost-effectiveness probability sensitivity analysis (n = 1000).
The fourth quadrant indicated that the flupentixol-melitracen + lansoprazole regimen is an advantageous solution (with good performance and low cost).
- Citation: Yin KH, Wang XY, Wang XY, Cheng L, Wang B, Wang QQ, Qiao Y, Tang XR, Yan XJ, Chen SL. Efficacy and safety of neuromodulators combined with proton pump inhibitors for non-erosive reflux disease: A randomized clinical trial. World J Gastroenterol 2026; 32(44): 122876
- URL: https://www.wjgnet.com/1007-9327/full/v32/i44/122876.htm
- DOI: https://dx.doi.org/10.3748/wjg.122876